New technologies for the identification of markers for early detection of ovarian cancer.
OBJECTIVE
The ovarian cancer screening regimens in current use fail to identify disease at an early curable stage.


RESULTS
New technologies are emerging that facilitate the identification of diagnostic tumor markers. In particular, high throughput techniques using microarray technology and proteomic screening have enriched the study of protein expression by ovarian cancer cells.


CONCLUSIONS
Further evaluation of serum proteins associated with ovarian cancer holds promise for the development of a tumor marker panel that could aid in the early diagnosis of ovarian cancer, and save lives.
Bandera
Christina A
CA
Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02138, USA. cabandera@partners.org
Ye
Bin
B
Mok
Samuel C
SC
D014408:Biomarkers, Tumor / Q000032:analysis*; D018394:CA-125 Antigen / Q000032:analysis*; D004273:DNA, Neoplasm / Q000032:analysis; D015180:Electrophoresis, Gel, Two-Dimensional / Q000379:methods*; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000097:blood / Q000175:diagnosis*; D011379:Prognosis; D012334:RNA, Neoplasm / Q000032:analysis; D012680:Sensitivity and Specificity; D013997:Time Factors
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D004273:DNA, Neoplasm; D012334:RNA, Neoplasm